397 related articles for article (PubMed ID: 24821849)
1. Risk of tuberculosis in patients with chronic immune-mediated inflammatory diseases treated with biologics and tofacitinib: a systematic review and meta-analysis of randomized controlled trials and long-term extension studies.
Souto A; Maneiro JR; Salgado E; Carmona L; Gomez-Reino JJ
Rheumatology (Oxford); 2014 Oct; 53(10):1872-85. PubMed ID: 24821849
[TBL] [Abstract][Full Text] [Related]
2. Comparative efficacy and safety of tocilizumab, rituximab, abatacept and tofacitinib in patients with active rheumatoid arthritis that inadequately responds to tumor necrosis factor inhibitors: a Bayesian network meta-analysis of randomized controlled trials.
Lee YH; Bae SC
Int J Rheum Dis; 2016 Nov; 19(11):1103-1111. PubMed ID: 26692536
[TBL] [Abstract][Full Text] [Related]
3. Risks of malignancies related to tofacitinib and biological drugs in rheumatoid arthritis: Systematic review, meta-analysis, and network meta-analysis.
Maneiro JR; Souto A; Gomez-Reino JJ
Semin Arthritis Rheum; 2017 Oct; 47(2):149-156. PubMed ID: 28284845
[TBL] [Abstract][Full Text] [Related]
4. Systematic review and meta-analysis of serious infections with tofacitinib and biologic disease-modifying antirheumatic drug treatment in rheumatoid arthritis clinical trials.
Strand V; Ahadieh S; French J; Geier J; Krishnaswami S; Menon S; Checchio T; Tensfeldt TG; Hoffman E; Riese R; Boy M; Gómez-Reino JJ
Arthritis Res Ther; 2015 Dec; 17():362. PubMed ID: 26669566
[TBL] [Abstract][Full Text] [Related]
5. Lipid profile changes in patients with chronic inflammatory arthritis treated with biologic agents and tofacitinib in randomized clinical trials: a systematic review and meta-analysis.
Souto A; Salgado E; Maneiro JR; Mera A; Carmona L; Gómez-Reino JJ
Arthritis Rheumatol; 2015 Jan; 67(1):117-27. PubMed ID: 25303044
[TBL] [Abstract][Full Text] [Related]
6. Tuberculosis and other opportunistic infections in tofacitinib-treated patients with rheumatoid arthritis.
Winthrop KL; Park SH; Gul A; Cardiel MH; Gomez-Reino JJ; Tanaka Y; Kwok K; Lukic T; Mortensen E; Ponce de Leon D; Riese R; Valdez H
Ann Rheum Dis; 2016 Jun; 75(6):1133-8. PubMed ID: 26318385
[TBL] [Abstract][Full Text] [Related]
7. The Impact of Biologics and Tofacitinib on Cardiovascular Risk Factors and Outcomes in Patients with Rheumatic Disease: A Systematic Literature Review.
Nurmohamed M; Choy E; Lula S; Kola B; DeMasi R; Accossato P
Drug Saf; 2018 May; 41(5):473-488. PubMed ID: 29318514
[TBL] [Abstract][Full Text] [Related]
8. A comparison of discontinuation rates of tofacitinib and biologic disease-modifying anti-rheumatic drugs in rheumatoid arthritis: a systematic review and Bayesian network meta-analysis.
Park SK; Lee MY; Jang EJ; Kim HL; Ha DM; Lee EK
Clin Exp Rheumatol; 2017; 35(4):689-699. PubMed ID: 28079510
[TBL] [Abstract][Full Text] [Related]
9. Real-world comparative risks of herpes virus infections in tofacitinib and biologic-treated patients with rheumatoid arthritis.
Curtis JR; Xie F; Yun H; Bernatsky S; Winthrop KL
Ann Rheum Dis; 2016 Oct; 75(10):1843-7. PubMed ID: 27113415
[TBL] [Abstract][Full Text] [Related]
10. Tuberculosis reactivation risk in dermatology.
Pescitelli L; Ricceri F; Prignano F
J Rheumatol Suppl; 2014 May; 91():65-70. PubMed ID: 24789002
[TBL] [Abstract][Full Text] [Related]
11. Adverse effects of biologics: a network meta-analysis and Cochrane overview.
Singh JA; Wells GA; Christensen R; Tanjong Ghogomu E; Maxwell L; Macdonald JK; Filippini G; Skoetz N; Francis D; Lopes LC; Guyatt GH; Schmitt J; La Mantia L; Weberschock T; Roos JF; Siebert H; Hershan S; Lunn MP; Tugwell P; Buchbinder R
Cochrane Database Syst Rev; 2011 Feb; 2011(2):CD008794. PubMed ID: 21328309
[TBL] [Abstract][Full Text] [Related]
12. Risk of tuberculosis reactivation associated with traditional disease modifying anti-rheumatic drugs and non-anti-tumor necrosis factor biologics in patients with rheumatic disorders and suggestion for clinical practice.
Cantini F; Niccoli L; Capone A; Petrone L; Goletti D
Expert Opin Drug Saf; 2019 May; 18(5):415-425. PubMed ID: 31066297
[TBL] [Abstract][Full Text] [Related]
13. Changes in Lipid Levels and Incidence of Cardiovascular Events Following Tofacitinib Treatment in Patients With Psoriatic Arthritis: A Pooled Analysis Across Phase III and Long-Term Extension Studies.
Gladman DD; Charles-Schoeman C; McInnes IB; Veale DJ; Thiers B; Nurmohamed M; Graham D; Wang C; Jones T; Wolk R; DeMasi R
Arthritis Care Res (Hoboken); 2019 Oct; 71(10):1387-1395. PubMed ID: 31112005
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of tofacitinib for moderate-to-severe plaque psoriasis: a systematic review and meta-analysis of randomized controlled trials.
Kuo CM; Tung TH; Wang SH; Chi CC
J Eur Acad Dermatol Venereol; 2018 Mar; 32(3):355-362. PubMed ID: 29136293
[TBL] [Abstract][Full Text] [Related]
15. Tuberculosis in biologic users for rheumatic diseases: results from the South African Biologics Registry (SABIO).
Pettipher C; Benitha R
Ann Rheum Dis; 2020 Feb; 79(2):292-299. PubMed ID: 31791950
[TBL] [Abstract][Full Text] [Related]
16. Analysis of infections and all-cause mortality in phase II, phase III, and long-term extension studies of tofacitinib in patients with rheumatoid arthritis.
Cohen S; Radominski SC; Gomez-Reino JJ; Wang L; Krishnaswami S; Wood SP; Soma K; Nduaka CI; Kwok K; Valdez H; Benda B; Riese R
Arthritis Rheumatol; 2014 Nov; 66(11):2924-37. PubMed ID: 25047021
[TBL] [Abstract][Full Text] [Related]
17. [Biologics and mycobacterial diseases].
Tsuyuguchi K; Matsumoto T
Kekkaku; 2013 Mar; 88(3):337-53. PubMed ID: 23672175
[TBL] [Abstract][Full Text] [Related]
18. Risk of serious adverse effects of biological and targeted drugs in patients with rheumatoid arthritis: a systematic review meta-analysis.
Tarp S; Eric Furst D; Boers M; Luta G; Bliddal H; Tarp U; Heller Asmussen K; Brock B; Dossing A; Schjødt Jørgensen T; Thirstrup S; Christensen R
Rheumatology (Oxford); 2017 Mar; 56(3):417-425. PubMed ID: 28013201
[TBL] [Abstract][Full Text] [Related]
19. Biologic therapy for inflammatory arthritis and latent tuberculosis: real world experience from a high prevalence area in the United Kingdom.
Nisar MK; Rafiq A; Östör AJ
Clin Rheumatol; 2015 Dec; 34(12):2141-5. PubMed ID: 26497501
[TBL] [Abstract][Full Text] [Related]
20. Cardiovascular safety findings in patients with rheumatoid arthritis treated with tofacitinib, an oral Janus kinase inhibitor.
Charles-Schoeman C; Wicker P; Gonzalez-Gay MA; Boy M; Zuckerman A; Soma K; Geier J; Kwok K; Riese R
Semin Arthritis Rheum; 2016 Dec; 46(3):261-271. PubMed ID: 27443588
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
